Adverse Pregnancy Outcomes and Incident Heart Failure in the Women's Health Initiative.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
01 12 2021
Historique:
entrez: 9 12 2021
pubmed: 10 12 2021
medline: 18 1 2022
Statut: epublish

Résumé

Some prior evidence suggests that adverse pregnancy outcomes (APOs) may be associated with heart failure (HF). Identifying unique factors associated with the risk of HF and studying HF subtypes are important next steps. To investigate the association of APOs with incident HF overall and stratified by HF subtype (preserved vs reduced ejection fraction) among postmenopausal women in the Women's Health Initiative (WHI). In 2017, an APO history survey was administered in the WHI study, a large multiethnic cohort of postmenopausal women. The associations of 5 APOs (gestational diabetes, hypertensive disorders of pregnancy [HDP], low birth weight, high birth weight, and preterm delivery) with incident adjudicated HF were analyzed. In this cohort study, the association of each APO with HF was assessed using logistic regression models and with HF subtypes using multinomial regression, adjusting for age, sociodemographic characteristics, smoking, randomization status, reproductive history, and other APOs. Data analysis was performed from January 2020 to September 2021. APOs (gestational diabetes, HDP, low birth weight, high birth weight, and preterm delivery). All confirmed cases of women hospitalized with HF and HF subtype were adjudicated by trained physicians using standardized methods. Of 10 292 women (median [IQR] age, 60 [55-64] years), 3185 (31.0%) reported 1 or more APO and 336 (3.3%) had a diagnosis of HF. Women with a history of any APO had a higher prevalence of hypertension, diabetes, coronary heart disease, or smoking. Of the APOs studied, only HDP was significantly associated with HF with a fully adjusted odds ratio (OR) of 1.75 (95% CI, 1.22-2.50), and with HF with preserved ejection fraction in fully adjusted models (OR, 2.06; 95% CI, 1.29-3.27). In mediation analyses, hypertension explained 24% (95% CI, 12%-73%), coronary heart disease 23% (95% CI, 11%-68%), and body mass index 20% (95% CI, 10%-64%) of the association between HDP and HF. In this large cohort of postmenopausal women, HDP was independently associated with incident HF, particularly HF with preserved ejection fraction, and this association was mediated by subsequent hypertension, coronary heart disease, and obesity. These findings suggest that monitoring and modifying these factors early in women presenting with HDP may be associated with reduced long-term risk of HF.

Identifiants

pubmed: 34882182
pii: 2786989
doi: 10.1001/jamanetworkopen.2021.38071
pmc: PMC8662370
mid: NIHMS1766310
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2138071

Subventions

Organisme : NHLBI NIH HHS
ID : T32 HL094301
Pays : United States

Références

Ann Epidemiol. 2003 Oct;13(9 Suppl):S122-8
pubmed: 14575944
Am J Obstet Gynecol. 1982 Dec 1;144(7):768-73
pubmed: 7148898
Circulation. 2011 May 10;123(18):2006-13; discussion 2014
pubmed: 21555723
Nurs Womens Health. 2020 Apr;24(2):91-100
pubmed: 32119830
Circ Cardiovasc Qual Outcomes. 2017 Feb;10(2):
pubmed: 28228456
Circ Heart Fail. 2012 Sep 1;5(5):571-8
pubmed: 22887722
Heart. 2015 Oct;101(19):1584-90
pubmed: 26243788
Eur Heart J. 2018 Oct 1;39(37):3439-3450
pubmed: 30165580
J Womens Health (Larchmt). 2015 Sep;24(9):702-12
pubmed: 26061196
Endocrinol Metab Clin North Am. 2019 Sep;48(3):479-493
pubmed: 31345518
Semin Perinatol. 2015 Jun;39(4):276-83
pubmed: 26117165
J Card Fail. 2020 Jan;26(1):2-12
pubmed: 31536806
J Am Heart Assoc. 2020 Jul 7;9(13):e013991
pubmed: 32578465
BJOG. 2018 Feb;125(3):336-341
pubmed: 28165208
ESC Heart Fail. 2017 May;4(2):88-98
pubmed: 28451444
Circulation. 2021 May 4;143(18):e902-e916
pubmed: 33779213
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
Control Clin Trials. 1998 Feb;19(1):61-109
pubmed: 9492970
Acta Diabetol. 2018 Apr;55(4):315-322
pubmed: 29327149
Circulation. 2019 Sep 24;140(13):1050-1060
pubmed: 31545680
J Am Soc Hypertens. 2014 Nov;8(11):820-6
pubmed: 25455007
JAMA. 2016 Mar 8;315(10):1026-33
pubmed: 26954411
Ann Epidemiol. 2003 Oct;13(9 Suppl):S18-77
pubmed: 14575939
Ann Epidemiol. 2003 Oct;13(9 Suppl):S107-21
pubmed: 14575943
Am J Obstet Gynecol. 2018 Jul;219(1):107.e1-107.e6
pubmed: 29630888
Trends Cardiovasc Med. 2011 Oct;21(7):188-93
pubmed: 22867697
J Am Heart Assoc. 2019 Nov 19;8(22):e013545
pubmed: 31698969
Heart. 2018 Mar;104(5):377-384
pubmed: 29305560
Epidemiol Rev. 2014;36:57-70
pubmed: 24025350
Circulation. 2013 Oct 15;128(16):e240-327
pubmed: 23741058
Curr Opin Cardiol. 2017 Mar;32(2):196-202
pubmed: 28092289
Am J Epidemiol. 2004 Dec 15;160(12):1152-8
pubmed: 15583367
Obstet Gynecol. 2018 May;131(5):e140-e150
pubmed: 29683911
Diabetes Care. 2010 Apr;33(4):768-73
pubmed: 20067968
JAMA Cardiol. 2020 Dec 1;5(12):1390-1398
pubmed: 32936228
Ann Intern Med. 2018 Aug 21;169(4):224-232
pubmed: 29971437
J Am Coll Cardiol. 2019 Dec 3;74(22):2743-2754
pubmed: 31727424
MMWR Morb Mortal Wkly Rep. 2018 Nov 02;67(43):1201-1207
pubmed: 30383743
J Womens Health (Larchmt). 2020 Oct;29(10):1283-1291
pubmed: 31934809
Maturitas. 2017 Dec;106:57-72
pubmed: 29150167
Hypertension. 2020 Dec;76(6):1828-1837
pubmed: 33012200
J Am Coll Cardiol. 2021 Mar 2;77(8):1057-1068
pubmed: 33632480
Eur Heart J. 2019 Dec 14;40(47):3859-3868c
pubmed: 31800034
Hypertension. 2020 Jun;75(6):1542-1550
pubmed: 32306767
BMJ. 2007 Nov 10;335(7627):974
pubmed: 17975258

Auteurs

Aleksander L Hansen (AL)

Steno Diabetes Center Odense, Odense University Hospital, Odense, Denmark.

Marc Meller Søndergaard (MM)

Aalborg University School of Medicine and Health, Aalborg, Denmark.

Mark A Hlatky (MA)

Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California.

Eric Vittinghof (E)

Department of Epidemiology and Biostatistics, University of California San Francisco School of Medicine, San Francisco.

Gregory Nah (G)

Department of Medicine, Division of Cardiology, University of California, San Francisco.

Marcia L Stefanick (ML)

Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California.

JoAnn E Manson (JE)

Department of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Leslie V Farland (LV)

Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson.

Gretchen L Wells (GL)

College of Medicine, University of Kentucky, Lexington.

Morgana Mongraw-Chaffin (M)

Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, North Carolina.

Erica P Gunderson (EP)

Lifecourse Epidemiology of Diabetes and Heart Disease in Women and Youth Division of Research, Kaiser Permanente Northern California, Oakland.

Linda Van Horn (L)

Feinberg School of Medicine, Northwestern University, Chicago, Illinois.

Robert A Wild (RA)

Department of Biostatistics and Epidemiology, Oklahoma University Health Sciences Center, Oklahoma City.
Department of Obstetrics and Gynecology, Oklahoma University Health Sciences Center, Oklahoma City.

Buyun Liu (B)

Department of Epidemiology, University of Iowa, Iowa City.

Aladdin H Shadyab (AH)

School of Medicine, University of California San Diego, La Jolla.

Matthew A Allison (MA)

School of Medicine, University of California San Diego, La Jolla.

Simin Liu (S)

Department of Epidemiology, Public Health Program, Brown University, Providence, Rhode Island.

Charles B Eaton (CB)

Alpert Medical School, Brown University, Pawtucket, Rhode Island.

Michael C Honigberg (MC)

Cardiology Division, Massachusetts General Hospital, Boston.
Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge.

Nisha I Parikh (NI)

Department of Medicine, Division of Cardiology, University of California, San Francisco.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH